Nav: Home

Brand drug discount cards increase private insurer costs by 46%

November 11, 2019

Discount cards for brand-name drugs provided to patients increased private insurer costs by 46% and varied in their impact on out-of-pocket payments by patients, found new research in CMAJ (Canadian Medical Association Journal).

"For private insurance plans, these cards were universally bad," says Dr. Michael Law, a Canada Research Chair at the School of Population and Public Health, University of British Columbia, Vancouver, BC. "Of the 89 different cards we studied, each and every one of them led to private insurance plans paying more."

Brand pharmaceutical companies have introduced patient discount cards in recent years to maintain market share as many generic versions have become available because of patent expiry. These cards provide patients with a discount on brand-name pharmaceuticals with generic equivalents to entice patients to purchase the brand-name drug.

Researchers analyzed data from 2.8 million prescriptions for 89 different medications for which brand discount cards were used. They then compared the costs of these prescriptions to matched generic equivalents.

Brand discount cards had little impact on public insurance plans, but in the case of private plans, the cost was always more for all 89 drugs. For the top 15 most popular drugs, private insurers paid between $2.90 and $46.91 more per brand drug prescription compared with generics.

"Only about half of private drug plans in Canada have rules whereby they will pay only the amount of the equivalent generic when one is available," write the authors. "Our study provides empiric evidence that drug discount cards represent a way for pharmaceutical companies to leverage this discrepancy while making patients' copayments nearly equivalent, so as not to deter them from filling their prescriptions with branded medicines."

"Given that our analysis showed large increases for private plans, employers might consider adopting more stringent generic substitution policies to ensure value for money in drug spending," write the authors.

The impact on out-of-pocket payments by patients varied a great deal in the study. While those with private insurance and no insurance saved $0.12 and $3.49 per prescription, respectively, those using public drug plans paid $1.86 more. These amounts varied substantially, however, from a savings of $13.44 to an increase of $11.71 for the most popular cards.

"Buyer beware," says Dr. Law. "People may think they will pay less, but they often end up paying more. It's a mixed bag in terms of benefits for patients."

The authors conclude that "regardless of whether they hold insurance, individuals should check relative prices at their pharmacy between the brand with a discount card and the equivalent generic, given the possibility that they may be worse off financially if they use a card."

In a linked commentary, Dr. Marc-André Gagnon, School of Public Policy and Administration, Carleton University, Ottawa, Ontario, writes, "(co-pay cards) may influence health care professionals to promote the message that brand-name products are better (by complying with patients' requests to specify 'no substitution' on prescriptions). They likely also waste resources, increase costs for patients (by increasing their insurance premiums) and may even incentivize patients to push for brand-name drugs through a mechanism that many might consider to border on institutionalized bribery."

These cards also potentially allow the transfer of patients' confidential clinical information to drug companies, which has raised serious concerns.
-end-
"Co-pay cards in Canada: Improving choice or institutionalizing bribes?" is published November 11, 2019

Canadian Medical Association Journal

Related Drugs Articles:

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.
A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.
Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.
Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.
Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.
New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.
New TB drugs possible with understanding of old antibiotic
Tuberculosis, and other life-threatening microbial diseases, could be more effectively tackled with future drugs, thanks to new research into an old antibiotic by the University of Warwick and the Francis Crick Institute.
Versatile cancer drugs
Medications which block enzymes belonging to the kinase family, are among the most effective pharmaceuticals for targeted cancer therapies.
When HIV drugs don't cooperate
Researchers at Thomas Jefferson University studying combinations of drugs against HIV have discovered why some drugs sometimes act synergistically but sometimes do not.
'Accelerated approval' drugs: How well are they studied?
In a recent study published in JAMA, researchers at Brigham and Women's Hospital and the London School of Economics and Political Science examined the pre-approval and post-approval clinical trials of drugs granted FDA Accelerated Approval between 2009 and 2013.
More Drugs News and Drugs Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#543 Give a Nerd a Gift
Yup, you guessed it... it's Science for the People's annual holiday episode that helps you figure out what sciency books and gifts to get that special nerd on your list. Or maybe you're looking to build up your reading list for the holiday break and a geeky Christmas sweater to wear to an upcoming party. Returning are pop-science power-readers John Dupuis and Joanne Manaster to dish on the best science books they read this past year. And Rachelle Saunders and Bethany Brookshire squee in delight over some truly delightful science-themed non-book objects for those whose bookshelves are already full. Since...
Now Playing: Radiolab

An Announcement from Radiolab